Results 231 to 240 of about 427,120 (360)

Akt/mTOR pathway-mediated CCNA1 regulation of radiotherapy resistance in nasopharyngeal carcinoma. [PDF]

Cell Oncol (Dordr)
Zeng R, Zhong L, Li P, Gao X, Chen Y, Hao W.   +5 more
europepmc   +1 more source

MTOR Inhibitor [PDF]

, 2020
openaire   +1 more source

Cancer Stem Cells Shift Metabolite Acetyl‐Coenzyme A to Abrogate the Differentiation of CD103+ T Cells

Advanced Science, EarlyView.
Lei et al. demonstrate that cancer stem cells (CSCs) play a pivotal role in impairing the differentiation of CD103+ T cells in patients with non‐small‐cell lung cancer. The key mechanism involves CSC‐derived acetyl‐CoA, which disrupts CD103+ T cell differentiation by sequentially inducing acetylation and ubiquitination of the Blimp‐1 protein. Targeting
Jiaxin Lei, Huiyan Ji, Jing Guo, Mengdi Liu, Danhua Su, Yiran Zheng, Lin Xu, Qinghua Cao, Tao Ren, Jun Gui, Zhenke Wen   +10 more
wiley   +1 more source

Dissociation of the mTOR Protein Interaction Network Following Neuronal Activation Is Altered by Shank3 Mutation. [PDF]

J Neurochem
Wehle DT, Brown EA, Stamenkovic V, Gniffen B, Harsh FM, Smith SEP.   +5 more
europepmc   +1 more source

Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor

, 2015
Yuichiro Kanno, Shuai Zhao, Naoya Yamashita, Kazuyuki Yanai, Kiyomitsu Nemoto, Yoshio Inouye   +5 more
openalex   +2 more sources

ITGB1 Regulates Triple‐Negative Breast Cancer Development by Modulating the Tumor Microenvironment

Advanced Science, EarlyView.
ABSTRACT Tumorigenesis and metastasis are frequently attributed to the intricate interplay between cancer cells and the tumor microenvironment (TME). Comprehending the mechanisms and key regulators of cancer‐immune crosstalk in the TME is imperative for developing efficacious immunotherapy.
Nuozi Song, Siqi Chen, Lei Wang, Jessica Dang, Xu Cao, Stephanie Singh, Lu Yang, Jinhui Wang, Steven T. Rosen, Yingyu Wang, Chun‐Wei D. Chen, Cheng Zhang, Mingye Feng   +12 more
wiley   +1 more source

Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma.

, 2013
Christina A. Von Roemeling, Laura A. Marlow, William P. Kennedy, Gregory T. Kennedy, John A. Copland, Michael E Menefee   +5 more
openalex   +1 more source

Combined Photothermal and mTOR‐Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study reveals that photothermal therapy, while inducing immunogenic cell death in triple‐negative breast cancer, paradoxically activates the oncogenic mTOR pathway to drive immune evasion. To counter this, a smart nanocomposite is engineered to co‐deliver localized hyperthermia and mTOR inhibition.
Yujie Zhao, Jing Yu, Xin Wang, Xu Liu, Fengli Zuo, Tianyue Xu, Leyi Tang, Ling Xiong, Li Li, Huifang Li, Xiaoting Chen, Guang Yang, Jing Jing, Xiaowei Liu   +13 more
wiley   +1 more source

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma. [PDF]

Clin Exp Med
Sun Y, Cheng Q, Zhou Q, Xu Y, Wang G, Xu C, Wang W, Cai S, Chen W.   +8 more
europepmc   +1 more source

Spatio‐Temporal Proteomic Landscape Reveals Early Warning Signals of Esophageal Squamous Cell Carcinoma Progression

Advanced Science, EarlyView.
This study constructs a proteomic atlas of esophageal squamous cell carcinoma (ESCC) progression using esophageal biopsy samples. It identifies moderate dysplasia as the critical turning stage and a seven‐protein panel for early detection. Functionally, GBP6 loss promotes ESCC progression via cell cycle and epithelial‐mesenchymal transition (EMT ...
Xumiao Li, Jie Yuan, Min Gao, Jibin Liu, Qinqin Wang, Yaqi Zhang, Mingtao Cao, Xiaolin Hu, Hui Yang, Jun Li, Chen Li, Xiaoguang Li, Hui Wang   +12 more
wiley   +1 more source